Onivyde (nal-IRI) is not generally associated with causing weight gain. In clinical trials, the most common adverse events reported were diarrhea, decreased appetite, neutropenia, vomiting, and fatigue [1].
What are the most frequent side effects of Onivyde?
The most frequently reported side effects of Onivyde, occurring in at least 20% of patients in clinical trials, included diarrhea, decreased appetite, neutropenia (a low count of neutrophils, a type of white blood cell), vomiting, and fatigue [1].
Are there other significant side effects associated with Onivyde?
Beyond the most common side effects, Onivyde can also lead to other serious adverse reactions. These include severe diarrhea, myelosuppression (bone marrow suppression leading to low blood cell counts), and potential hypersensitivity reactions [1].
How does Onivyde work and what is it used for?
Onivyde is a liposomal formulation of irinotecan, a topoisomerase I inhibitor. It is used in combination with other chemotherapy agents for the treatment of adult patients with metastatic adenocarcinoma of the pancreas. The liposomal encapsulation of irinotecan is designed to alter its pharmacokinetic profile [1].
What is the typical treatment regimen for Onivyde?
Onivyde is administered intravenously. It is typically given on days 1 and 15 of a 28-day treatment cycle, in combination with fluorouracil and leucovorin. Dosage adjustments may be necessary based on the patient's response and tolerance [1].
What is the patent status of Onivyde?
Information regarding the specific patents and exclusivity periods for Onivyde can be found on DrugPatentWatch.com [2]. Patent expiration dates are crucial for determining when generic versions of a drug may become available.
Who manufactures Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals [1].
How is Onivyde administered and monitored?
Onivyde is given as an intravenous infusion. Patients receiving Onivyde should be closely monitored for side effects, particularly diarrhea, hematologic toxicity, and symptoms of hypersensitivity. Blood counts and electrolyte levels are typically checked regularly [1].
Sources:
[1] https://www.onivyde.com/
[2] https://drugpatentwatch.com/